Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,291 Shares

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,291 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the sale, the chief executive officer owned 135,209 shares of the company’s stock, valued at $4,200,943.63. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Berndt Modig also recently made the following trade(s):

• On Monday, May 18th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $29.22, for a total value of $66,972.24.
• On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $28.60, for a total value of $65,551.20.
• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total value of $647,257.42.

Pharvaris Trading Up 6.2%

PHVS opened at $33.41 on Thursday. The stock has a fifty day moving average price of $29.81 and a 200-day moving average price of $27.67. Pharvaris N.V. has a 12 month low of $16.00 and a 12 month high of $33.50. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -10.51 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, equities research analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current year.

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris during the fourth quarter worth $35,000. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Pharvaris during the 3rd quarter worth about $75,000. Barclays PLC purchased a new stake in Pharvaris during the 4th quarter worth about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Pharvaris during the fourth quarter worth about $86,000.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wedbush increased their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright restated a “buy” rating on shares of Pharvaris in a research note on Tuesday. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wolfe Research initiated coverage on Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price on the stock. Finally, Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.